3 Reasons the Market Is Down on Gilead Sciences
Gilead Sciences's competition from AbbVie and Merck is just one of the reasons.
After a solid two-year run, Gilead Sciences (NASDAQ:GILD) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie (NYSE:ABBV)and Merck (NYSE:MRK) around the corner.
In the slideshow below, you'll find three reasons investors are down on Gilead Sciences and thoughts on the biotech's future.